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H epatocellular carcinoma (HCC) is a common cancer with a high incidence and rate of mortal-
ity worldwide [1].  Although the majority of HCC cases 
occur in Asia and Africa,  the incidence of HCC has 
increased even in developed nations.  Several therapeu-
tic options are available for the treatment of HCC; the 
selection of treatment is based on the stage of HCC,  the 
patient’s residual liver function and comorbidities,  and 
the local clinical expertise.  In Japan,  sorafenib became 
the standard first-line therapy for the treatment of 
advanced HCC in 2009 based on the results and guide-
lines of the SHARP [2] and Asian-Pacific [3] studies,  
with evidence that sorafenib provides ≥ 3-month 
increase in survival.  Important baseline predictors of 
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The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma 
(HCC) has not been established.  We measured the SMM in HCC patients treated with sorafenib,  evaluated the 
patients’ survival,  and evaluated the association between skeletal muscle depletion and sorafenib treatment.  Of 
the 97 HCC patients treated with sorafenib at our institution in the period from July 2009 to February 2015,  
our study included 69 patients (51 males,  18 females) who had received sorafenib for ≥ 8 weeks and whose fol-
low-up data were available.  SMM was calculated from computed tomography images at the mid-L3 level (cm2) 
and normalized to height (m2) to yield the L3 skeletal muscle index (L3-SMI,  cm2/m2).  The median L3-SMI 
value was higher in the males (43 cm2/m2) compared to the females (36 cm2/m2).  In the males only,  the multi-
variate Cox regression identified an L3-SMI < 43 cm2/m2 as independently associated with higher mortality 
compared to an L3-SMI ≥ 43 cm2/m2 (hazard ratio 2.315,  95% confidence interval: 1.125-4.765,  p= 0.023).  
Skeletal muscle depletion is a factor predicting poor prognosis for male patients with advanced HCC treated 
with sorafenib.
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the survival of patients with advanced HCC are the lev-
els of alpha-fetoprotein (AFP) and vascular endothelial 
growth factor,  the Child-Pugh score,  and macrovascu-
lar invasion of the tumor have been identified as 
important baseline predictors of the survival of patients 
with advanced HCC [4].
Skeletal muscle depletion,  also referred to as sarco-
penia,  has been identified as a factor predicting poor 
prognosis for patients undergoing chemotherapy for 
various carcinomas,  including colorectal cancer [5],  
pancreatic cancer [6],  and esophageal cancer [7].  The 
association between skeletal muscle depletion and 
prognosis in patients with HCC was evaluated by Iritani 
et al.  [8],  who reported that skeletal muscle depletion 
was an independent prognostic factor in HCC treat-
ment outcomes.  Two factors compelled us to further 
evaluate age-related sarcopenia in Japan in relation to 
the treatment of HCC.  First,  the population of elderly 
people in Japan already comprises a large segment of the 
general population,  and it is growing rapidly.  Secondly,  
due to the improved management of patients with 
chronic liver diseases,  the mean age of patients with 
HCC has also been steadily rising [9].  In fact,  for HCC 
patients with good liver function and good perfor-
mance status,  appropriate treatment can improve their 
chances of survival,  even among extremely elderly 
patients [10].  The accurate evaluation of skeletal muscle 
mass (SMM) is therefore warranted in patients under-
going treatment for HCC.
Computed tomography (CT) imaging provides 
detailed anatomical information on specific muscles,  
adipose tissues and organs,  and CT is useful for pre-
dicting whole-body composition [11].  Skeletal muscle 
depletion,  estimated by the cross-sectional area of sev-
eral muscles at the level of the third lumbar vertebra 
(L3),  has been associated with a higher mortality rate in 
patients with liver cirrhosis,  independent of Child-
Pugh scores and Model for End stage Liver Disease 
(MELD) scores [12 , 13].  To allow for between-subject 
comparisons,  the measured muscle cross-sectional 
areas at L3 are normalized to the square of an individu-
al’s height (m2) to yield the skeletal muscle index at L3 
(L3-SMI,  cm2/m2) [12].
Other techniques for evaluating body composition 
and providing a measure of SMM have been described 
in the literature and are used in research and practice,  
including bioelectrical impedance analysis,  magnetic 
resonance imaging (MRI),  dual-energy X-ray absorpti-
ometry,  and ultrasonography [14 , 15].  Due to the ret-
rospective nature of our present study,  we used a 
CT-based method to calculate the L3-SMI [16] and 
subsequently evaluated the association between L3-SMI 
and the prognosis of patients with HCC treated with 
sorafenib.
Although the association between skeletal muscle 
depletion and the prognosis of HCC patients treated 
with sorafenib has been examined,  the precise associa-
tion has not been established [17 , 18].  There is a defi-
nite need to more completely evaluate the association 
between skeletal muscle depletion and outcomes of 
sorafenib therapy in HCC.  We conducted this study to 
elucidate whether skeletal muscle depletion predicts 
survival in HCC patients treated with sorafenib.
Patients and Methods
Patient characteristics and follow-up method.
Sorafenib was administered to 97 patients with HCC at 
our hospital in the period from July 2009 to February 
2015.  Of this group,  69 patients who had received 
sorafenib for > 8 weeks and whose follow-up data were 
available formed our study population; 51 males and 18 
females (mean age 70.7 ± 8.8 years old).  The clinical 
stage of HCC was determined using the staging system 
of the Japanese Liver Cancer Study Group (JLCSG) [19].  
The clinical indications for treatment using sorafenib 
were based on the 2013 Clinical Practice Guidelines for 
Hepatocellular Carcinoma of the Japan Society of 
Hepatology (available from: http://www.jsh.or.jp/
English/examination_en, accessed Mar. 2017) [20].  The 
patient’s responses to treatment were evaluated using the 
modified Response Evaluation Criteria in Solid Tumors 
(mRECIST) guidelines [21].  Clinical images were 
obtained by dynamic CT and MRI.  Overall survival 
(OS) was calculated as the period from the date at 
which sorafenib therapy was initiated to the date of 
death or until March 2015 for surviving patients.
Image evaluation of SMM. Each patient’s SMM 
was calculated using CT images obtained prior to the 
initiation of sorafenib therapy.  The cross-sectional area 
of the following skeletal muscles was measured at the 
mid-L3 level: psoas,  erector spinae,  quadratus lumbo-
rum,  transversus abdominis,  external and internal 
obliques,  and rectus abdominis.  The cross-sectional 
areas were calculated using commercial segmentation 
software (Synapse Vincent,  Fujifilm,  Tokyo,  Japan) 
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[16 , 22].  Calculated cross-sectional areas (cm2) were 
normalized by the square of the individual’s height (m2) 
to obtain the normalized L3-SMI (cm2/m2) [8].  The 
total visceral fat area at the mid-L3 level (L3-fat) was 
measured using the same technique.  Based on the dif-
ference in body mass composition for men and women,  
we performed separate analyses for the 2 genders.
Statistical analysis. Categorical data were com-
pared using Fisher’s exact test,  and continuous data 
using Wilcoxon’s test.  Survival was evaluated using the 
Kaplan-Meier method,  with differences examined using 
the log-rank test.  Survival was also evaluated using a 
multivariate analysis with the Cox proportional hazards 
regression model.  Although the univariate analyses did 
not show significant differences in the tested factors 
(except for L3-SMI) among the male patients,  we ana-
lyzed the Child-Pugh score,  clinical stage,  and AFP 
(which are common prognostic factors) in a multivari-
ate analysis.  P-values < 0.05 were considered significant.  
All statistical analyses were performed using the IBM 
Statistical Package for the Social Sciences software ver.  
21 (SPSS 21,  IBM,  NY,  USA).
The study protocol conformed to the ethical guide-
lines of the Declaration of Helsinki and was approved by 
our institutional ethics review committee.  The partici-
pants’ informed consent was not required,  due to the 
retrospective nature of our study.
Results
Patient background. The distribution of the 
underlying etiology of HCC among the 69 patients was 
as follows: hepatitis B (6/69,  9%),  hepatitis C (44/69,  
64%),  excessive alcohol use (7/69,  10%),  and other 
conditions such as non-alcoholic steatohepatitis (2/69,  
3%) and primary biliary cirrhosis (1/69,  1%),  which 
were regrouped into one category of “other” (12/69,  
17%).  In terms of the clinical stage of the disease,  62 
patients were classified as Child-Pugh grade A,  and the 
other seven patients were classified as grade B.
The impact of HCC on the patients’ daily function-
ing was evaluated using the Eastern Cooperative 
Oncology Group Performance Status (ECOG PS) scale 
and criteria.  The distribution of ECOG PS grades was as 
follows: 51 patients had the ECOG PS grade of 0 (i.e.,  
fully active,  able to carry on all pre-disease activities 
without restriction); 15 had the ECOG PS grade of 1 
(i.e.,  restricted from physically strenuous activity but 
ambulatory and able to carry out work of a light or sed-
entary nature); and the remaining 3 patients had the 
ECOG PS grade of 2 (ambulatory,  up and about > 50% 
of waking hours,  and capable of all self-care,  but 
unable to carry out any work activities).  The classifica-
tion of the clinical stage using the JLCSG system was 
confirmed: 0 patients at stage I; seven at stage II; 34 at 
stage III; 13 at stage IV-A; and 15 at stage IV-B.  The 
median L3-SMI was 42 cm2/m2,  and the median L3-fat 
index was 78 cm2/m2.  The median initial dose of 
sorafenib was 400 mg/day (Table 1).
L3-SMI level-based comparison of background 
characteristics. We divided the 69 patients into two 
groups using the median L3-SMI (42 cm2/m2) as a cut-
off,  and we compared background characteristics 
between the low L3-SMI ( < 42 cm2/m2) group (n = 35) 
and the high L3-SMI group ( ≥ 42 cm2/m2; n = 34) 
(Table 2).  There were significantly fewer women in the 
high L3-SMI group compared to the low L3-SMI group.  
Based on this difference,  we decided to analyze the 
prognostic factors for sorafenib treatment separately for 
the men and the women.
Regardless of gender,  there were no significant dif-
ferences between the low and high L3-SMI groups in 
terms of the Child-Pugh score,  previous treatment for 
HCC,  clinical stage using the JLCSG classification sys-
tem,  level of AFP,  levels of proteins induced by vitamin 
K absence (PIVKA-II),  or the initial dose of sorafenib.  
The patients’ age,  body mass index (BMI),  and L3-fat 
index values were higher in the high L3-SMI group 
compared to the low L3-SMI group.
Patient outcomes of sorafenib treatment. Of the 
51 males in our patient population,  38 died due to 
tumor progression and hepatic failure.  The median sur-
vival time (MST) was 12 months,  with 1- and 2-year 
survival rates of 50.6% and 25.4%,  respectively.  Among 
the 18 female patients,  12 died due to tumor progres-
sion and hepatic failure.  The MST of the female patients 
was 14.8 months,  with 1-,  and 2-year survival rates of 
71.1% and 39.1%,  respectively.  Although the MST was 
better for the women,  this between-sex difference was 
not significant.  There was also no significant difference 
between the low L3-SMI ( < 42 cm2/m2) and the high 
L3-SMI ( ≥ 42 cm2/m2) groups in terms of the OS (log-
rank test,  p = 0.466; Fig. 1A).
The males were dichotomized based on the group 
median L3-SMI of 43 cm2/m2 and the MST compared 
between the high and low L3-SMI groups.  For men in 
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the high L3-SMI group,  the MST was 13.5 months,  
with 1-,  and 2-year survival rates of 57.6% and 36.0%,  
respectively.  By comparison,  for men in the low 
L3-SMI group,  the MST was 7.6 months,  with 1-,  and 
2-year survival rates of 39.7% and 11.3%,  respectively.  
The OS was therefore significantly longer for the men 
with an L3-SMI ≥ 43 cm2/m2 compared to those with an 
L3-SMI < 43 cm2/m2 (log-rank test,  p = 0.044; Fig. 1B).
We also divided the female patients into 2 groups by 
the median L3-SMI among women (36 cm2/m2).  There 
was no significant difference in OS between the low 
L3-SMI ( < 36 cm2/m2) and high L3-SMI ( ≥ 36 cm2/m2) 
female groups (log-rank test,  p = 0.675; Fig. 1C).
Prognostic factors for patients with advanced HCC.
We first identified prognostic factors of survival for 
male HCC patients treated with sorafenib by using the 
Cox proportional hazards model.  Among the 8 vari-
ables identified in Table 3a,  only L3-SMI < 43 cm2/m2 
was significantly associated with OS in the univariate 
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Table 1　 Patient characteristics
Characteristics Parameter Patients n (%)
No. of patients 69 (100)
Gender
Male 51 (74)
Female 18 (26)
Age,  year
Median 72
Range 49-87
Etiology
HCV 44 (64)
HBV 6 (9)
Alcohol 7 (10)
Others 12 (17)
Child-Pugh grade
A 62 (90)
B 7 (10)
ECOG PS
0 51 (74)
1 15 (22)
2 3 (4)
Previous treatment
TACE 44 (64)
HAIC 24 (35)
RFA 9 (13)
Surgery 9 (13)
Radiation 1 (1)
None 7 (10)
Clinical stage of JLCSG
II 7 (10)
III 34 (49)
IV-A 13 (19)
IV-B 15 (22)
AFP (ng/ml)
Median 95
Range 2-104410
PIVKA-II (mAU/ml)
Median 155
Range 10-53500
BMI (kg/m2)
Median 24
Range 16-35
L3-SMI (cm2/m2)
　all patients Median 42
Range 27-60
L3-SMI of male Median 43
Range 31-60
L3-SMI of female Median 36
Range 27-55
L3-fat (cm2/m2)
Median 78
Range 12-215
Initial dose of sorafenib (mg)
100 10 (15)
200 21 (30)
300 1 (1)
400 27 (39)
600 1 (1)
800 9 (14)
HCV,  hepatitis C virus; HBV,  hepatitis B virus; ECOG,  Eastern Coop-
erative Oncology Group; PS,  performance status; TACE,  transarterial 
chemoembolization; HAIC,  hepatic arterial infusion chemotherapy; RFA,  
radiofrequency ablation; JLCSG,  Japanese Liver Cancer Study Group;  
AFP,  alpha fetprotein; PIVKA-II,  Proteins induced by vitamin K absence;  
BMI,  body mass index; L3-SMI,  L3-Skeletal muscle index.
Table 2　 Background of patients according to the L3-SMI level
Characteristics L3-SMI＜42 L3-SMI≥42 P value
Number of patient 35 34
Gender (male/female) 21/14 30/4 0.008
Age (yr) 73.8±7.4 67.6±9.1 0.005
(60-87) (49-86)
Child-Pugh score 5.4±0.8 5.4±0.7 0.623
Previous treatment
(－/＋)
4/31 3/31 0.720
Clinical stage of JLCSG 
(II,  III/IV)
21/14 20/14 0.921
AFP (ng/ml) 5,689±18,078 783±1,935 0.139
(2-104410) (2.8-9883)
PIVKA-II (mAU/ml) 6,238±14,653 1,471±3,314 0.415
(10-53500) (19-17700)
BMI (kg/m2) 21.6±2.7 26.2±3.8 ＜0.001
(16.1-27.2) (19.7-35.5)
L3-SMI (cm2/m2) 35.7±4.2 49.8±4.7 ＜0.001
(27.1-42.9) (43.1-60.1)
L3-fat (cm2/m2) 60.2±30.0 109.2±43.4 ＜0.001
(11.5-119.6) (37.9-215.5)
Initial dose of sorafenib 
(mg)
0.711
＜400 17 15
≥400 18 19
JLCSG,  Japanese Liver Cancer Study Group; AFP,  alpha fetprotein;  
PIVKA-II,  proteins induced by vitamin K absence; BMI,  body mass index-
; L3-SMI,  L3-Skeletal muscle index.  Data were revealed as the mean 
value ± standard deviation.  Ranges were shown in each parentheses.  
Wilcoxonʼs test was used to compare the medians of each variables 
between the 2 groups.  Categorical data were compared using Fisherʼs 
exact test.
analysis,  with a hazard ratio (HR) of 1.916 and 95% 
confidence interval (CI) of 1.008-3.642 (p = 0.047).  In 
addition,  L3-SMI < 43 cm2/m2 was an independent 
prognostic factor for male HCC patients treated with 
sorafenib in our multivariate analysis (HR 2.315,  95% 
CI: 1.125-4.765,  p = 0.023).  The patients in the low 
SMM group (L3-SMI < 43 cm2/m2) had a poor survival 
rate (Fig. 1B).
We next attempted to identify the prognostic factors 
of survival for female HCC patients treated with 
sorafenib using the Cox proportional hazards model.  
Among the eight variables listed in Table 3b,  L3-fat 
(HR 0.273,  95% CI: 0.080-0.932,  p = 0.038) and the 
initial dose of sorafenib (HR 0.073,  95% CI: 0.009-
0.601,  p = 0.015) were significantly associated with OS 
in the univariate analyses.  However,  no prognostic 
factors for the female HCC patients treated with 
sorafenib were identified in the multivariate analysis 
(Table 3b).
Adverse effects in male HCC patients. Over the 
study period,  13 of the 51 males were forced to discon-
tinue the sorafenib treatment due to adverse effects,  
with sorafenib discontinued in another 25 due to dis-
ease progression.  The adverse effects included the fol-
lowing: abnormal levels of alanine aminotransferase 
(n = 3),  hepatic coma (n = 2),  cerebral hemorrhage 
(n = 1),  cerebral infarction (n = 1),  gastrointestinal 
bleeding (n = 1),  sepsis (n = 1),  intestinal pneumonitis 
(n = 1),  general fatigue (n = 1),  abdominal pain (n = 1),  
and diarrhea (n = 1).
In the Cox proportional hazards model,  we searched 
for prognostic factors of sorafenib discontinuation in 
male patients.  Among the nine variables listed in Table 
4,  no prognostic factor was significantly associated with 
the discontinuation of sorafenib treatment in our uni-
variate analysis.  The initial dose of sorafenib ( < 800 vs.  
800 mg) was associated with a nonsignificant trend 
toward sorafenib discontinuation (HR 3.676,  95% 
CI: 0.976-13.846,  p = 0.054; Table 4).
Discussion
Sorafenib is an oral small-molecule inhibitor of 
intracellular tyrosine and serine/threonine protein 
kinases,  with anti-proliferative and anti-angiogenic 
activities.  Sorafenib has been approved worldwide as a 
first-line therapy for patients with advanced HCC who 
are ineligible for surgical resection,  locoregional abla-
tion,  and transarterial embolization [2 , 3].  The identi-
fication of prognostic factors for the effective use of 
sorafenib is clinically important to optimize treatment 
outcomes.
August 2017 Skeletal Muscle Depletion and Sorafenib 295
Female onlyMale onlyAll patients
p=0.675p=0.466 p=0.044
A B C
O
ve
ra
ll 
su
rv
iv
al
 r
at
e
O
ve
ra
ll 
su
rv
iv
al
 r
at
e
O
ve
ra
ll 
su
rv
iv
al
 r
at
e
Days Days Days
Fig. 1　 Kaplan-Meier curves for overall survival (OS) in all patients,  the males only,  and the females only.  Each group was divided into 
2 arms based on their respective L3 skeletal muscle index (L3-SMI) median.  (A) Subgroup comparison based on the L3-SMI among all 
patients.  There was no diﬀerence between the L3-SMI ＜42 cm2/m2 and L3-SMI ≥42 cm2/m2 groups in the OS period (log-rank test,  p＝
0.466).  (B) The male patients only.  The OS period was signiﬁcantly longer for the male patients in the L3-SMI ≥43 cm2/m2 group com-
pared to those in the L3-SMI ＜43 cm2/m2 group (log-rank test,  p＝0.044).  (C) The female patients only.  There was no signiﬁcant diﬀer-
ence in the OS period between the L3-SMI ＜36 cm2/m2 and L3-SMI ≥36 cm2/m2 groups (log-rank test,  p＝0.675).
Llovet et al.  reported that angioprotein 2 (a bio-
marker of angiogenesis) and vascular endothelial 
growth factor are independent predictors of survival in 
patients with advanced HCC [23].  However,  the mea-
surement of angiogenesis biomarkers is difficult in 
practice.  In our multivariate analysis,  we identified the 
L3 skeletal muscle index as an independent negative 
prognostic factor of OS in male HCC patients being 
treated with sorafenib (Table 3a).  This finding is not 
completely surprising based on emerging evidence of 
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Table 3　 Prognostic factors for overall survival in patients with advanced HCC
(a) male
Prognostic factors
Univariate analysis Multivariate analysis
Hazard ratio 95%CI P value Hazard ratio 95%CI P value
Age (＜70 year vs. ≥70) 0.950 0.500-1.803 0.950
Child-Pugh score (5 vs. ≥6) 1.614 0.799-3.261 0.182 1.927 0.856-4.338 0.113
Clinical stage (II,  III vs. IV) 1.425 0.753-2.696 0.276 1.894 0.937-3.828 0.075
AFP (＜400 vs. ≥400 ng/ml) 1.213 0.630-2.338 0.563 1.082 0.482-2.428 0.849
BMI (＜24 vs. ≥24 kg/m2) 0.937 0.491-1.791 0.845
L3-SMI (≥43 vs. ＜43 cm2/m2) 1.916 1.008-3.642 0.047 2.315 1.125-4.765 0.023
L3-fat (＜85 vs. ≥85 cm2/m2) 1.059 0.554-2.025 0.862
Initial dose of sorafenib (＜400 vs. ≥400 mg) 1.119 0.575-2.177 0.741
AFP,  alpha fetprotein; BMI,  body mass index; L3-SMI,  L3-Skeletal muscle index.
(b) female
Prognostic factors
Univariate analysis Multivariate analysis
Hazard ratio 95%CI P value Hazard ratio 95%CI P value
Age (＜70 year vs. ≥70) 3.135 0.819-11.999 0.095 0.960 0.148-6.216 0.966
Child-Pugh score (5 vs. ≥6) 2.856 0.794-10.272 0.108 0.422 0.054-3.318 0.412
Clinical stage (II,  III vs. IV) 0.610 0.174-2.141 0.440
AFP (＜400 vs. ≥400 ng/ml) 0.492 0.106-2.287 0.366
BMI (＜24 vs. ≥24 kg/m2) 1.582 0.504-4.964 0.432
L3-SMI (≥36 vs. ＜36 cm2/m2) 1.279 0.404-4.045 0.675 1.835 0.372-9.040 0.456
L3-fat (＜61 vs. ≥61 cm2/m2) 0.273 0.080-0.932 0.038 0.338 0.070-1.638 0.178
Initial dose of sorafenib (＜400 vs. ≥400 mg) 0.073 0.009-0.601 0.015 0.063 0.004-1.010 0.051
AFP,  alpha fetprotein; BMI,  body mass index; L3-SMI,  L3-Skeletal muscle index.
Table 4　 Univariate analysis for discontinuation risk of sorafenib due to its toxicity in male patients by Cox proportional hazards model
Prognostic factors
Univariate analysis
Hazard ratio 95%CI P value
Age (＜70 year vs. ≥70) 0.703 0.226-2.188 0.543
Child-Pugh score (5 vs. ≥6) 1.423 0.419-4.862 0.574
Clinical stage (II,  III vs. IV) 1.425 0.457-4.444 0.541
AFP (＜400 vs. ≥400 ng/ml) 1.173 0.350-3.927 0.796
BMI (＜24 vs. ≥24 kg/m2) 1.408 0.442-4.483 0.562
L3-SMI (≥43 vs. ＜43 cm2/m2) 1.610 0.516-5.019 0.412
L3-fat (＜85 vs. ≥85 cm2/m2) 0.606 0.182-2.018 0.415
Initial dose of 
　sorafenib (＜400 vs. ≥400 mg) 1.504 0.449-5.035 0.508
　sorafenib (＜800 vs. 800 mg) 3.676 0.976-13.846 0.054
AFP,  alpha fetprotein; BMI,  body mass index; L3-SMI,  L3-Skeletal muscle index.
the negative impact of age-related sarcopenia on the 
health outcomes of elderly individuals.  Sarcopenia is 
defined as an age-related involuntary loss of SMM and 
strength [24],  and sarcopenia has been associated with 
a high risk for infections,  longer hospitalization,  greater 
need for rehabilitation care after hospital discharge,  and 
higher mortality rate for various diseases [25].
Depending on the cause of onset,  sarcopenia can be 
classified as being either primary or secondary.  Primary 
sarcopenia is considered age-related when no underly-
ing cause is evident other than aging itself.  Secondary 
sarcopenia,  in contrast,  is considered when one or 
more other causes are evident,  such as decreased phys-
ical activity,  disease,  or poor nutrition [26].  Ishii et al.  
estimated the prevalence of sarcopenia in functionally 
independent,  community-dwelling Japanese adults ≥ 65 
years old as 14.2% in men and 22.1% in women [27].
Patients with chronic liver disease are at risk for sar-
copenia,  with rapid skeletal muscle wasting being pre-
dictive of poor survival in patients with liver cirrhosis 
[28].  The normalized L3-SMI,  as we used in the pres-
ent study,  has been reported before and used in 
research.  However,  we identified significant sex differ-
ences in the L3-SMI.  Based on these differences,  we 
judged that it was not appropriate to evaluate prognostic 
factors for men and women combined,  as was done in 
the previous studies [17 , 18].  Rather,  we evaluated 
prognostic factors separately for men and women.  
Thus,  the present study is the first to analyze the 
sex-specific association between SMM and sorafenib 
treatment for HCC.
Although a low L3-SMI level ( < 43 cm2/m2) was 
associated with a poor prognosis for our male patients 
with advanced HCC and treated with sorafenib,  no 
prognostic factors for the female patients were identi-
fied in the multivariate analysis.  In addition,  we ana-
lyzed the OS in all patients,  the men only,  and the 
women only using the Kaplan-Meier method and the 
log-rank test.  We divided these three groups into 2 
arms using their respective L3-SMI medians.  Although 
the OS of the low and high L3-SMI arms did not differ 
in the OS period among all patients and among the 
women-only groups,  the male patients in the high 
L3-SMI arm showed significantly better OS compared 
to the male patients in the low L3-SMI arm,  similar to 
the results of the multivariate analyses.  The small num-
ber of patients in the female group (n = 18) could have 
contributed to the lack of significant prognostic factors 
in women.  Future studies should examine a sufficiently 
large number of patients with HCC of both sexes to 
evaluate possible sex-specific differences in prognostic 
factors without bias.
We also performed an L3-SMI level-based compari-
son of the patients’ background characteristics.  The 
ratio of females,  age,  BMI,  and L3-fat were higher in 
the high L3-SMI group compared to the low L3-SMI 
group.  In our multivariate analyses,  BMI and L3-fat 
were not significant prognostic factors for the men or 
the women.  Overall,  these results suggest that aspects 
of body compositions such as the SMM and fat should 
be assessed in HCC patients to better predict their prog-
nosis.
Mir et al.  reported associations among sarcopenia 
and sorafenib-related toxicities,  the need to reduce the 
dosage,  and the discontinuation of sorafenib [29].  
However,  we did not identify an association between 
L3-SMI and sorafenib discontinuation in our study 
(Table 4),  which confirms findings reported by Imai et 
al.  [17].  Our use of a lower dose than the standard ini-
tial dose of 800 mg/day may explain this result.  In par-
ticular,  the dose was ≤ 400 mg/day in 44 of our 51 male 
patients (86%) (Table 1).  These low doses of sorafenib 
might improve patients’ adherence to therapy,  possibly 
by lowering the incidence of adverse effects.
Morimoto et al.  reported that use of an initial half-
dose of sorafenib (i.e.,  400 mg/day) led to fewer severe 
adverse effects and a comparable survival benefit,  com-
pared with a full dose in selected patients with HCC,  
particularly for those of advanced age [30].  In our 
study,  the use of high-dose sorafenib (i.e.,  800 mg vs.  
< 800 mg) was associated with a tendency toward early 
discontinuation of the therapy (HR 3.676,  95% 
CI: 0.976-13.846,  p = 0.054; Table 4).
Our study adds to previous evidence of a positive 
effect of maintaining SMM on the prognosis of HCC 
patients.  It was reported that sarcopenia significantly 
increases the risk for mortality in patients with liver 
cirrhosis,  with evidence of a benefit of branched chain 
amino acid (BCAA) supplementation for improving 
survival in these patients [13].  Two randomized con-
trolled trials from Italy and Japan confirmed the bene-
fits of BCAA supplementation in reducing the duration 
of cirrhosis-related hospitalization,  as well as cirrho-
sis-related deaths [31 , 32].
A recent multicenter retrospective cohort study by 
Imanaka et al.  showed that BCAA improved the sur-
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vival prognosis in HCC patients treated with sorafenib 
[33].  BCAA supplementation may improve adherence 
to sorafenib by maintaining liver function and SMM,  
and by improving the patients’ general health status,  
resulting in a longer-term administration of sorafenib 
and a prolonged OS.
The etiology of sarcopenia in the elderly is 
multi-factorial in nature,  and the prevention of sarco-
penia during the prehospitalization stage would be 
important to improve the prognosis of patients with 
HCC.  Wakabayashi et al.  proposed a comprehensive 
approach to sarcopenia treatment in elderly patients,  
including pharmaceutical therapies for age-related sar-
copenia and comorbid chronic diseases,  resistance 
training,  speed walking,  nutrition management,  pro-
tein and amino acid supplementation,  and support for 
cessation of smoking,  as needed [26].  Although such a 
comprehensive program can be successfully imple-
mented on an in-patient basis,  it may be difficult to 
sustain over the longer term,  even for elderly individu-
als who are facing health problems related to sarcope-
nia.  As a solution,  Yamada et al.  provided evidence of 
the benefits of a 6-month mall-based walking program 
in combination with nutritional supplementation for 
preventing sarcopenia in community-dwelling older 
adults [34].  This community-based approach is prom-
ising and could be useful as a large population-based 
approach for the prevention of sarcopenia and frailty 
among community-dwelling elderly people.
The limitations of our study should be acknowl-
edged in the interpretation and application of our 
results.  Foremost,  we were unable to evaluate prognos-
tic factors in the female HCC patients treated with 
sorafenib due to their low number (n = 18).  In addition,  
we only evaluated L3-SMI as a variable of skeletal mus-
cle,  with no evaluation of the quality of the strength of 
skeletal muscles.  The consensus report of the Asian 
Working Group for Sarcopenia recommends that sarco-
penia be defined through a combined measure of SMM 
and muscle quality,  evaluated by handgrip strength or 
usual gait speed [24].  It is possible that an evaluation of 
both SMM and muscle quality could identify more 
accurate prognostic factors.
In conclusion,  the quantification of SMM using CT 
imaging at the mid-L3 level could provide a useful tech-
nique for predicting the prognosis of patients with 
HCC,  including those treated with sorafenib.  As skele-
tal muscle depletion was identified as a factor predicting 
poor prognosis among patients with advanced HCC,  
the prevention of skeletal muscle depletion may be an 
important component of therapeutic interventions to 
improve survival prognosis in male HCC patients.  
Prospective studies are needed to confirm the relation-
ship between skeletal muscle depletion and prognosis,  
as well as to investigate prognostic factors in female 
patients with advanced HCC treated with sorafenib.
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